Journey Medical Q2 2024 GAAP EPS $(0.17) Misses $(0.14) Estimate, Sales $14.855M Beat $13.880M Estimate
Portfolio Pulse from Benzinga Newsdesk
Journey Medical (NASDAQ:DERM) reported Q2 2024 GAAP EPS of $(0.17), missing the $(0.14) estimate, but sales of $14.855M beat the $13.880M estimate. EPS improved from $(0.46) last year, while sales decreased from $17.172M.
August 12, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Journey Medical (NASDAQ:DERM) reported Q2 2024 GAAP EPS of $(0.17), missing the $(0.14) estimate by 21.43%. However, sales of $14.855M beat the $13.880M estimate by 7.02%. EPS improved from $(0.46) last year, but sales decreased from $17.172M.
The mixed results, with EPS missing but sales beating estimates, create a neutral short-term impact. The improvement in EPS from last year is positive, but the decline in sales is a concern.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100